In a report released on January 5, Ryan Zimmerman from BTIG maintained a Buy rating on Glaukos (GKOS – Research Report), with a price target of $90.00. The company’s shares closed last Friday at $79.11.
Zimmerman covers the Healthcare sector, focusing on stocks such as Glaukos, Vericel, and Hologic. According to TipRanks, Zimmerman has an average return of 7.8% and a 45.40% success rate on recommended stocks.
Currently, the analyst consensus on Glaukos is a Moderate Buy with an average price target of $88.00, representing an 11.24% upside. In a report released on December 26, Wells Fargo also maintained a Buy rating on the stock with a $83.00 price target.
See the top stocks recommended by analysts >>
Based on Glaukos’ latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $78.05 million and a GAAP net loss of $30.44 million. In comparison, last year the company earned a revenue of $67.68 million and had a net profit of $5.4 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Glaukos (GKOS) Company Description:
Glaukos Corp. is an ophthalmic medical device company, which engages in the development and commercialization of surgical devices and sustained pharmaceutical therapies designed to treat glaucoma. Its Micro Invasive Glaucoma Surgery procedures are designed to reduce intraocular eye pressure by improving aqueous outflow through the natural physiologic pathway. The company was founded by Olav B. Bergheim, Morteza Gharib, and Richard Hill on July 14, 1998 and is headquartered in San Clemente, CA.
Read More on GKOS:
- MIGS LCD withdrawals ‘takes some upside off table’ for Glaukos, says Truist
- Palmetto GBA announcement creates uncertainty for Glaukos, says BTIG
- Glaukos price target raised to $100 from $88 at Truist
- Glaukos price target raised to $105 from $90 at Piper Sandler
- Glaukos upgraded to Overweight from Neutral at JPMorgan
